Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 18, 2004. The report details a specific corporate action regarding the repurchase of the company's own shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2004.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 800,000 Ordinary shares of 25 pence each.
- Purchase Date: November 17, 2004.
- Price Per Share: 1,204.3396 pence.
- Treasury Holdings Post-Purchase: 54,028,000 shares.
- Shares in Issue (Excluding Treasury): 5,882,651,805 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program. The company increased its Treasury share holdings by 800,000 shares. No other material changes to operations or financial position are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 800,000 share repurchase based on the disclosed price of 1,204.3396 pence per share.
- Confirm the updated total share count (5,882,651,805 in issue) against subsequent filings to ensure accuracy.
- Review the company's broader capital allocation strategy to understand the context of this specific buyback within the full fiscal year.